The Who, What, and When of Immunizations
As the world scrambles to find a vaccine for the newest coronavirus, appropriate use of existing vaccines remains vital for immunosuppressed patients. Current vaccination guidelines, however, are open to interpretation.
Many patients with either malignant...
Online Exclusives
Novo Nordisk Halts Concizumab Trials After Thrombotic Events
After observing blood clots in some patients enrolled in clinical trials of concizumab, Novo Nordisk has paused one mid-stage and two late-stage studies of...
Scientists Scour FDA-Approved Drugs for Potential Coronavirus Treatment
As part of a working group spread across 22 laboratories, a team of scientists at the University of California, San Francisco (UCSF)–based Quantitative Biosciences...
News
From the Blood Journals
Can Dasatinib Overcome the Negative Effects of KIT Mutations in Core...
A chemotherapy regimen of cytarabine and daunorubicin plus dasatinib was well tolerated in patients with previously untreated core binding factor acute myeloid leukemia (CBF-AML)...
Metabolic Syndrome Predicts Risk of Recurrent VTE in Patients With Newly...
Patients with newly diagnosed deep vein thrombosis (DVT) who have components of metabolic syndrome – hypertension, hyperlipidemia, diabetes mellitus, or obesity – have a...
Multimedia
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline...
Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis
Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...
On Location
Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL
The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of...
Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL
Nearly half of patients with relapsed/refractory acute lymphocytic leukemia (ALL) had a complete response (CR)...
Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma
Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) followed by autologous transplant and Dara-KRd...
Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with...
Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?
Results from the Intergroup National Clinical Trials Network (NCTN) study S1001 demonstrated that 89% of...
DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma
In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of...
Latest Headlines
ASH Directions
Nominate Yourself or a Colleague for an ASH Leadership Position, and more
Clinical Practitioners: Nominate Yourself or a Colleague for an ASH Leadership Position
American Society of Hematology (ASH) members in good standing can nominate themselves or...
ASH Releases Clinical Practice Guidelines on SCD-Related Transfusion Support, Opens Access to LLS’ Clinical...
ASH Releases Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
The American Society of Hematology (ASH) has released new clinical practice guidelines on Sickle...
Remembering Clara Bloomfield, City of Hope Appoints Eileen Smith as Head of Hematology, and...
Remembering Clara Bloomfield, MD (1942 – 2020)
Leukemia scientist Clara Bloomfield, MD, died on March 1, 2020 at the age of 77.With more than 50...
David H. Koch Center Opens at MSKCC, Sidney Kimmel Welcomes Usama Gergis, and more
Patrick White Appointed Chair in Palliative Medicine and Supportive Care
Patrick White, MD, director of the Division of Palliative Medicine at Washington University School of...
Moffitt Officials Resign, HHS Awards $319 Million to National Health Service Corps, and more
Edward P. Evans Foundation Awards $10 Million in Funding for MDS Research
Washington University School of Medicine in St. Louis and Dana-Farber Cancer Institute in...
The Who, What, and When of Immunizations
As the world scrambles to find a vaccine for the newest coronavirus, appropriate use of existing vaccines remains vital for immunosuppressed patients. Current vaccination...
What’s a Life Worth and Who Gets to Decide?
In an ideal world, all patients would receive the best possible care regardless of cost. However, since wealth is unevenly distributed and there are...
Extinguishing Smoldering Myeloma?
For patients with smoldering myeloma – a precursor stage of multiple myeloma (MM) – the standard approach for years has been “watch and wait,”...
